Treatment of cutaneous pseudolymphoma with interferon alfa-2b Sanjay Tomar, MD, Howard L. Stoll, MD, Marcelle A. Grassi, MD, Richard Cheney, MD Journal of the American Academy of Dermatology Volume 60, Issue 1, Pages 172-174 (January 2009) DOI: 10.1016/j.jaad.2008.07.052 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Skin lesions of pseudolymphoma on the back. Journal of the American Academy of Dermatology 2009 60, 172-174DOI: (10.1016/j.jaad.2008.07.052) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Low-power image showing a dense superficial and deep perivascular lymphotic infiltrate. No dermal mucin or interface change is identified. (Hematoxylin–eosin stain; original magnification: ×2.) Journal of the American Academy of Dermatology 2009 60, 172-174DOI: (10.1016/j.jaad.2008.07.052) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Deep perivascular lymphocytic aggregate with well developed germinal center and a mantle of small- to medium-sized lymphocytes. (Hematoxylin–eosin stain; original magnification: ×20.) Journal of the American Academy of Dermatology 2009 60, 172-174DOI: (10.1016/j.jaad.2008.07.052) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 Resolution of the skin lesions after treatment with intralesional interferon alfa-2b. Journal of the American Academy of Dermatology 2009 60, 172-174DOI: (10.1016/j.jaad.2008.07.052) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions